placebo + AIR001

placebo + AIR001 refers to the comparative administration of a placebo and AIR001 (sodium nitrite inhalation solution) within clinical trial protocols, specifically those conducted by Aires Pharmaceuticals for pulmonary arterial hypertension (PAH). AIR001 is a nebulized small molecule therapeutic designed to deliver sodium nitrite directly to the lungs. Once inhaled, sodium nitrite is converted into nitric oxide (NO) through a process independent of nitric oxide synthase activity. The resulting NO acts upon soluble guanylate cyclase, increasing levels of cyclic guanosine monophosphate (cGMP), which promotes vasodilation, reduces inflammation, and inhibits undesirable cell growth in the pulmonary vasculature. This specific combination name typically appears in the context of crossover or dose-finding studies where subjects receive both a placebo and the active drug to establish safety and pharmacodynamic baselines under conditions such as hypoxia.

Brand names

Aironite

Other names

sodium nitriteSodium Nitrite Inhalation Solution